This study is looking at whether AXS-05 can help prevent depressive symptoms from returning in people with Major Depressive Disorder (MDD). You could be eligible if you are between 18 and 65 years old, have MDD without psychotic features, and your current depressive episode has lasted at least 4 weeks. You cannot have participated in a previous study of AXS-05 or taken certain other medications recently. The study will first give all participants AXS-05 for up to 10 weeks. If your depression improves, you will then be randomly assigned to continue AXS-05 or switch to bupropion for up to 26 weeks. The main goal is to see how long it takes for depressive symptoms to return in each group. The current recruitment status is unclear.

Study design

This is a randomized, double-blind, active-controlled study involving about 350 participants. It compares AXS-05 to bupropion.

What's involved

You would receive AXS-05 for up to 10 weeks, followed by up to 26 weeks of either AXS-05 or bupropion.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed for up to 26 weeks to see if depressive symptoms return.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.